Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs InstaRX

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and InstaRX head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 284 · Grade C

InstaRX

Visit InstaRX Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 64 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make InstaRX a bad call — it's best for readers who want to understand the care arrangement before requesting a complete named-medication quote and financial agreement. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
58
Supply Reliability
95
65
Transparency
90
48
Access Breadth
93
90
Clinical Oversight
92
73
Track Record
88
58
CoreAge RxBrief Score 94 · 64InstaRX

Price, coverage & the tracker

CoreAge RxInstaRX
Brief Score94/100 (A)64/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

Confirm current medication quote

Compounded semaglutide program named; generic $199 page title is not a complete named-drug quote. Earlier $199/month observation is historical.

Terms include a $45 consultation within monthly pricing, not an additional fee; final supply, term and refund milestones unknown.

Full price details

Compounded semaglutide offered; current complete medication quote unknown; generic homepage title starts at $199 without a named-drug period; earlier $199/month semaglutide observation is historical

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

Confirm current medication quote

Compounded tirzepatide program named; generic $199 title does not establish its price or billing period. Earlier $199/month observation is historical.

Subscriptions renew unless canceled before renewal; actual patient refund answers were not readable in the public page when reviewed.

Full price details

Compounded tirzepatide offered; current complete medication quote unknown; generic homepage title starts at $199 without a named-drug period; earlier $199/month tirzepatide observation is historical

CoverageUS only; restrictions by state, confirmed at intakeAdvertises service across all fifty states and D.C.; actual clinician, pharmacy and selected-treatment eligibility require confirmation
Brand-name accessNot confirmedReviewed named GLP-1 programs are compounded; current branded prescribing was not established.
Oral / sublingualInjection onlyUnconfirmed
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

InstaRX: Complete current named-drug quotes unconfirmed. Generic $199 title does not assign a billing period or price to both molecules; earlier monthly observations remain historical.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.